

Observational study; An open-label, phase 2a imaging study to assess the utility off 99mTc-NC100692 injection in post-MI patients to predict risk of developing chronic heart failure.

Gepubliceerd: 20-09-2007 Laatste bijgewerkt: 18-08-2022

The hypothesis of the present study is to demonstrate that detection of a particular pattern (e.g., persistent vs. non-persistent) of myocardial (alpha)V(beta)3/5 expression by scintigraphy imaging at 3 and 8 weeks after MI can be used to determine...

Ethische beoordeling	Positief advies
Status	Werving gestopt
Type aandoening	-
Onderzoekstype	Observationeel onderzoek, zonder invasieve metingen

Samenvatting

ID

NL-OMON22503

Bron

Nationaal Trial Register

Verkorte titel

N/A

Aandoening

1. Myocardial Infarction (hartinfarct);
2. Heart Failure (hartfalen).

Ondersteuning

Primaire sponsor: GE Healthcare Ltd., and its affiliates

Overige ondersteuning: GE Healthcare Ltd., and its affiliates

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

To investigate the relationship between the myocardial (alpha)V(beta)3/5 expression by scintigraphy at 3 weeks, at 8 weeks and the change from 3 to 8 weeks after MI and signs of a poor post-MI prognosis based on occurrence of MACE and/or signs of developing HF evident from worsening in the measured echocardiography variables LVEF, WMA, LVID and MR in the 6-month and 12-month follow-up period.

Toelichting onderzoek

Achtergrond van het onderzoek

In order to determine a patient's risk of developing full-blown HF, it is necessary to detect signs of the disease at an early, non-symptomatic stage and before substantial loss of myocardial function occurs, thereby enabling physicians to make effective therapeutic decisions (e.g., interventions and changes in medical treatment). The expression of (alpha)V(beta)3 on myofibroblasts is linked to active fibrosis, which is the hallmark of remodelling. This study will determine in 40 patients (with a run-in of 10 patients) whether detection of a particular pattern (e.g., persistent vs. non-persistent) of myocardial (alpha)V(beta)3/5 expression by 99mTc-NC100692 Injection scintigraphy imaging at 3 and 8 weeks after MI can be used to determine the longer-term risk of developing HF.

Doel van het onderzoek

The hypothesis of the present study is to demonstrate that detection of a particular pattern (e.g., persistent vs. non-persistent) of myocardial (alpha)V(beta)3/5 expression by scintigraphy imaging at 3 and 8 weeks after MI can be used to determine the longer-term risk of developing heart failure (HF).

Onderzoeksopzet

N/A

Onderzoeksproduct en/of interventie

Baseline:

Nuclear myocardial perfusion imaging, at rest and stress, using a thallium 201- or technetium 99m-labelled agent and according to the hospital's routines, to establish the extent of

myocardium remaining non-perfused.

All subjects will receive administration of 99mTc-NC100692 Injection at 3 and 8 weeks after MI and undergo SPECT imaging. Injection of 5.5 ml of 99mTc-NC100692 Injection at a rate of 2-4 ml per second. Each subject will receive +/-69 µg of NC100692 and a maximum 99mTc activity of 1 GBq/injection. An intravenous line (large bore catheter) should be established with a cannula valve for administration of 99mTc-NC100692 Injection. A suitable injection site will be chosen for each subject. After administration, the line should be flushed with 5 ml of Sodium Chloride (0.9% w/v). Subjects will receive the first injection 3 weeks after MI and the second injection 8 weeks after MI (nominal time points that may vary by ± 3 days).

Echocardiography \pm Doppler will be performed at all time points (baseline, 3+8weeks, 6+12months) to establish post-MI "baseline" values for left ventricular ejection fraction (LVEF), wall motion abnormalities (WMA), left ventricular internal dimensions (LVID) and mitral valve regurgitation (MR).

Contactpersonen

Publiek

Dept. of Cardiology
University Hospital Maastricht
P. Debeyelaan 25

Leonard Hofstra
Maastricht 6202 AZ
The Netherlands
+31-43-3877097

Wetenschappelijk

Dept. of Cardiology
University Hospital Maastricht
P. Debeyelaan 25

Leonard Hofstra
Maastricht 6202 AZ
The Netherlands
+31-43-3877097

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

Subjects may be included in the study if they meet all of the following criteria:

1. The subject has had no previous MI, presents with acute MI and has undergone coronary angiography during which percutaneous coronary intervention (PCI) or no intervention may be performed.
2. The subject is >18 years of age at study entry.
3. The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained, including permission to access coronary angiography records (see inclusion criterion No.1), before any study procedure is carried out;
4. The subject is male, or a female who is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom the result of a urine pregnancy test performed before administration of IMP is negative;
5. The subject has been clinically stable (e.g., not experiencing continuing chest pain or haemodynamic instability) for at least 7 days before each imaging session with 99mTc-NC100692 Injection*

* this inclusion criterion will be asked at 3 and 8 weeks post-MI.

Inclusion criterion for subjects with a presumed high post-MI likelihood of developing heart failure:

6. The subject has an LVEF of <40% and/or is NYHA class 3-4;

Inclusion criterion for subjects with a presumed low post-MI likelihood of developing heart failure:

7. The subject has an LVEF of >40% and is NYHA class 1-2.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

Subjects must be excluded from participating in this study if they meet any of the following criteria:

1. The subject was previously entered into this study or has participated in any other investigational medicinal product (IMP) study within 30 days of study entry.
2. The subject is scheduled to receive another IMP from time of entry into this study until completion of the follow-up period proposed for this study.
3. The subject has known allergies to any product used in this study or its constituents (e.g., para-amino benzoic acid).
4. The subject undergoes monitoring of occupational radiation exposure.
5. The subject presents with any other clinically active, serious, life-threatening disease with a life expectancy of less than 12 months or where participation in the study might compromise the management of the subject or for any other reason that in the judgement of the investigator(s) makes the subject unsuitable for participation of the study.
6. The subject is scheduled to have a revascularisation procedure (e.g., PCI or CABG) or cardiac transplant in the 30 days after study entry.
7. The subject participated in a research study using ionising radiation within 12 months of study entry.

Onderzoeksopzet

Opzet

Type:	Observationeel onderzoek, zonder invasieve metingen
Onderzoeksmodel:	Anders
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

Deelname

Nederland	
Status:	Werving gestopt
(Verwachte) startdatum:	05-10-2005
Aantal proefpersonen:	40
Type:	Werkelijke startdatum

Ethische beoordeling

Positief advies

Datum: 20-09-2007

Soort: Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL1039
NTR-old	NTR1072
Ander register	: protocol number ANG207; EudraCT 2005-002153-42
ISRCTN	ISRCTN wordt niet meer aangevraagd

Resultaten

Samenvatting resultaten

N/A